Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study

Haematologica. 2019 Feb;104(2):e63-e64. doi: 10.3324/haematol.2018.199794. Epub 2018 Aug 31.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Clinical Trials, Phase I as Topic
  • Drug Resistance, Neoplasm
  • Humans
  • Lenalidomide / administration & dosage*
  • Lenalidomide / adverse effects
  • Leukemia, Myeloid, Acute / diagnosis
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / etiology
  • Recurrence
  • Retreatment
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Lenalidomide